Envío mundial con seguimiento | Aprox. 9–14 días hábiles

Tu carrito

Tu carrito está vacío

Comenzar a explorar

Envío gratuito en pedidos superiores a €500.

Subtotal€0
Proceder al pago
RecuperaciónSolo preclínico

TB-500 + BPC-157

Investigación publicada y base de evidencia

One published study has directly tested BPC-157 and TB-500 together against each agent alone, and it found no additive benefit. Beyond that single rat Achilles tendon experiment and one retrospective human chart review in which some knee-pain patients received BPC 157 combined with thymosin beta-4, there is no peer-reviewed evidence for the combination. All other support is component-level: the two peptides have separate preclinical literatures that have been reviewed together in sports-medicine journals, but no synergy has been demonstrated in any model.

En resumen
  • BPC-157 y TB-500 son dos péptidos revisados juntos en revistas de medicina deportiva.
  • Un estudio en ratas no encontró beneficio adicional al combinarlos para lesión de tendón.
  • Ningún ensayo humano ha probado la combinación y no se ha demostrado sinergia alguna.

9 estudios · 6 desde 2023 · más reciente 2026

Estudios citados
9
Publicados en 2023+
6
Artículo más reciente
2026
Última revisión
oct 2026

Temas recurrentes en la literatura

  • combination versus monotherapy tendon healing
  • convergence on shared downstream repair pathways
  • absence of demonstrated synergy
  • sports medicine gray-market peptide stacking

La evidencia

9 estudios publicados.

Ordenados por solidez del diseño del estudio, luego por antigüedad. Cada entrada enlaza a su registro fuente para que el hallazgo pueda verificarse contra el artículo en lugar de tomarse bajo nuestra palabra.

  1. 01Revisión sistemática2026

    Peptide Supplements and Their Therapeutic Applications in Sports Medicine

    Tewari K, et al. · Am J Sports Med · PRISMA-guided scoping review of six peptides including BPC-157 and TB-500 against musculoskeletal tissue outcomes

    Sixty-seven percent of the identified literature used preclinical animal models and human clinical studies were limited to a handful of investigations. The review reported each compound separately and identified no combination trials.

  2. 02Revisión sistemática2025

    Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

    Vasireddi N, et al. · HSS J · systematic review of the BPC-157 musculoskeletal literature

    The review synthesised preclinical evidence for fracture, tendon, ligament and muscle healing and recorded the compound's lack of FDA approval and its prohibited status in professional sport. No combination studies were included.

  3. 03Clínico humano2021

    Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

    Lee E, Padgett B · Altern Ther Health Med · retrospective chart review at a single private clinic, 2019-2020; 17 patients given intra-articular BPC 157 alone or combined with thymosin beta-4, telephone follow-up in 16

    The review recorded self-rated pain change after intra-articular injection of BPC 157 alone or with thymosin beta-4. It used no validated outcome instruments and no control group, and did not separate combination recipients from monotherapy recipients in a way that permits inference about combination effect. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

  4. 04Animal in vivo2026

    Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study

    Biçer O, et al. · Jt Dis Relat Surg · rat Achilles tendon transection and repair; 32 male Sprague-Dawley rats in 4 groups of 8 including a dedicated BPC-157 + TB-500 combination arm; intraperitoneal dosing for 4 weeks

    This is the only published study to test the combination against each peptide alone. The combination group showed significantly lower total Movin scores than controls, but the authors stated explicitly that combined treatment did not confer additional benefit compared with either agent alone, and hypothesised convergence on shared downstream pathways.

  5. 05Animal in vivo2021

    Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats

    Japjec M, et al. · Biomedicines · rat myotendinous junction defect created by dissecting the quadriceps tendon from the quadriceps muscle

    BPC 157 improved macroscopic, microscopic, biomechanical and functional outcomes at the myotendinous junction, with associated changes in eNOS and COX-2 mRNA and in nitric oxide levels. Component-level evidence only.

  6. 06Animal in vivo1999

    Thymosin beta4 accelerates wound healing

    Malinda KM, et al. · J Invest Dermatol · rat full-thickness dermal wound model; topical or intraperitoneal thymosin beta4

    Thymosin beta4 increased re-epithelialisation by 42 percent at 4 days and up to 61 percent at 7 days versus saline controls, with increased collagen deposition and angiogenesis. Component-level evidence only.

  7. 07Revisión2026

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK, et al. · Am J Sports Med · narrative review of injectable peptide therapies including BPC-157, TB-4 and TB-500

    The review found BPC-157 showed potential in tendon and muscle repair that is largely unvalidated in human trials, noted the single human knee case series and its methodological limitations, and stated that TB-4 and TB-500 promoted angiogenesis and tissue repair in preclinical models while human orthopaedic data are lacking.

  8. 08Revisión2026

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

    Mendias CL, et al. · Sports Med · narrative review of approved and unapproved peptides marketed direct to patients, covering both BPC-157 and Tb4/TB-500

    The review reported favourable animal-model tissue repair outcomes for several unapproved peptides alongside scarce human safety data, and discussed placebo effects and social media amplification as mediators of perceived efficacy. It did not identify combination evidence.

  9. 09Revisión2026

    Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.

    Moiz A, et al. · Mo Med · narrative clinical review of unregulated injectable peptides

    Named both BPC-157 and TB-500 among unapproved peptides lacking established human safety profiles and described risks of contamination, impurities, inaccurate dosing, pathological angiogenesis and carcinogenesis.

    Hallazgo de seguridad reportado. Authors flagged contamination, impurities and theoretical angiogenesis/carcinogenesis risks for both unregulated peptides.

Limitaciones

Lo que esta evidencia no establece.

The single controlled experiment of this combination found no additive benefit over monotherapy, and it was a four-week exploratory rat study with eight animals per group. There is no human trial of the combination, no dose-optimisation work, no long-term follow-up, and no published evidence of pharmacological synergy in any tissue.

Preguntas comunes sobre la investigación.

Why are BPC-157 and TB-500 studied together?

The two peptides have separate preclinical literatures that converge on overlapping tissue-repair endpoints, and sports-medicine reviews have appraised them side by side for that reason. That convergence is the stated rationale for pairing them rather than a demonstrated pharmacological interaction. No published work has shown synergy between the two in any model or species.

Has the BPC-157 and TB-500 combination been tested against each peptide alone?

Once. A 2026 experiment in 32 male Sprague-Dawley rats with Achilles tendon transection and repair compared a control group, BPC-157 at 10 ug/kg/day, TB-500 at 60 ug/kg/day and a dedicated combination arm, with intraperitoneal dosing over four weeks. The combination group showed significantly lower total Movin scores than controls, but the authors stated explicitly that combined treatment did not confer additional benefit over either peptide given alone. The TB-500 group additionally showed a significantly higher maximum load to failure.

Is there any human evidence for the combination?

There is no human trial of the combination. The only human record is a 2021 retrospective chart review at a single private clinic covering 17 patients who received intra-articular BPC 157 alone or combined with thymosin beta-4, with telephone follow-up in 16. That review used no validated outcome instruments and no control group, and did not separate combination recipients from monotherapy recipients in a way that would allow the combination to be assessed.

Disponible en nuestro catálogo

Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico, y ningún estudio resumido aquí debe leerse como una recomendación.